GLP-1 Market
LLY $1123.00 ▼ -0.1% NVO $44.01 ▼ -1.2% PFE $27.65 ▼ -0.5% VKTX $32.13 ▼ -1.7% KLRA $14.91 ▲ +0.5% GPCR $39.55 ▼ -4.1% RHHBY $53.19 ▼ -0.4% HIMS $27.44 ▼ -1.6% WW $14.78 ▼ -1.1%
Delayed · As of 9:20 AM

Empowering you to have better conversations with your doctor.

Subscribe
About this data Sourced primarily from ClinicalTrials.gov — a listing isn't proof of safety or FDA approval.

Pipeline and clinical trial information here comes primarily from ClinicalTrials.gov. A listing on ClinicalTrials.gov means a study has been registered — not that a treatment is proven safe, effective, or FDA-approved. Investigational treatments may never be approved. Who can join a trial is decided only by that trial's own study team.

Not yet reported

LY2606368

Company
Dana-Farber Cancer Institute
Mechanism
Mechanism not yet reported
Route
Route not yet reported
Recruiting trials
2 recruiting

Efficacy results: Not yet reported

Find a Clinical Trial Near Me

2 recruiting studies currently listed on ClinicalTrials.gov.

Data source: ClinicalTrials.gov · trial data as of Sep 11, 2026

Find a Clinical Trial Near Me

See recruiting studies for LY2606368 and check eligibility with the study team.

Select conditions
Match
Treatment type

"Added to GLP-1" means the investigational treatment is being studied on top of an existing GLP-1-based therapy.

Your ZIP code is only used to calculate distance to trial sites — it isn't stored.

Trial details
  • Recruiting NCT NCT05548296

    A Phase 2 Study of ACR-368 in Endometrial Adenocarcinoma

    Not yet reported Acrivon Therapeutics 350 participants Est. completion 2027-11-30 90 sites
    Other conditions: Endometrial Adenocarcinoma
    View official trial listing →
  • Recruiting NCT NCT06597565

    A Phase II Study of ACR-368 and Low Dose Gemcitabine in R/M HNSCC

    Not yet reported H. Lee Moffitt Cancer Center and Research Institute 43 participants Est. completion 2028-08-23 1 site
    Other conditions: Head and Neck Squamous Cell Carcinoma
    View official trial listing →
  • Completed NCT NCT01115790

    A Phase 1 Study in Participants With Advanced Cancer

    Not yet reported Eli Lilly and Company 150 participants Est. completion 2016-01 5 sites
    Other conditions: Advanced Cancer, Squamous Cell Carcinoma, Carcinoma, Squamous Cell of Head and Neck, Lung Squamous Cell Carcinoma Stage IV, Anal Squamous Cell Carcinoma, Carcinoma, Non-Small-Cell Lung
    View official trial listing →
  • Completed NCT NCT02124148

    A Study of Prexasertib (LY2606368) With Chemotherapy or Targeted Agents in Participants With Advanced Cancer

    Not yet reported Eli Lilly and Company 167 participants Est. completion 2020-02-13 5 sites
    Other conditions: Neoplasm Metastasis, Colorectal Neoplasms, Breast Cancer
    View official trial listing →
  • Terminated NCT NCT02203513

    A Phase II Single Arm Pilot Study of the Chk1/2 Inhibitor (LY2606368) in BRCA1/2 Mutation Associated Breast or Ovarian Cancer, Triple Negative Breast Cancer, High Grade Serous Ovarian Cancer, and Metastatic Castrate-Resistant Prostate Cancer

    Not yet reported National Cancer Institute (NCI) 111 participants Est. completion 2021-08-27 1 site Stand-alone
    Other conditions: Ovarian Cancer, Breast Cancer, Prostate Cancer
    View official trial listing →
  • Completed NCT NCT02514603

    A Study of Prexasertib (LY2606368) in Japanese Participants With Advanced Cancers

    Not yet reported Eli Lilly and Company 12 participants Est. completion 2017-04-10 2 sites
    Other conditions: Neoplasm
    View official trial listing →
  • Completed NCT NCT02555644

    A Study of Prexasertib (LY2606368) With Chemotherapy and Radiation in Participants With Head and Neck Cancer

    Not yet reported Eli Lilly and Company 70 participants Est. completion 2019-01-14 4 sites
    Other conditions: Head and Neck Neoplasms
    View official trial listing →
  • Completed NCT NCT02649764

    Prexasertib (LY2606368), Cytarabine, and Fludarabine in Patients With Relapsed or Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome

    Not yet reported M.D. Anderson Cancer Center 15 participants Est. completion 2022-07-12 1 site Stand-alone
    Other conditions: Chronic Myelomonocytic Leukemia, Recurrent Acute Myeloid Leukemia, Recurrent High Risk Myelodysplastic Syndrome, Refractory Acute Myeloid Leukemia, Refractory High Risk Myelodysplastic Syndrome
    View official trial listing →
  • Completed NCT NCT02735980

    A Study of Prexasertib (LY2606368) in Participants With Extensive Stage Disease Small Cell Lung Cancer

    Not yet reported Eli Lilly and Company 133 participants Est. completion 2019-02-12 41 sites
    Other conditions: Small Cell Lung Cancer
    View official trial listing →
  • Completed NCT NCT02778126

    A Study of Prexasertib (LY2606368) in Participants With Advanced Cancer

    Not yet reported Eli Lilly and Company 6 participants Est. completion 2017-07-27 1 site
    Other conditions: Advanced Cancer
    View official trial listing →
  • Completed NCT NCT02808650

    Prexasertib in Treating Pediatric Patients With Recurrent or Refractory Solid Tumors

    Not yet reported Children's Oncology Group 30 participants Est. completion 2021-03-31 21 sites
    Other conditions: Childhood Solid Neoplasm, Recurrent Malignant Solid Neoplasm, Recurrent Primary Central Nervous System Neoplasm, Refractory Malignant Solid Neoplasm, Refractory Primary Central Nervous System Neoplasm
    View official trial listing →
  • Completed NCT NCT02860780

    A Study of Prexasertib (LY2606368) in Combination With Ralimetinib in Participants With Advanced or Metastatic Cancer

    Not yet reported Eli Lilly and Company 9 participants Est. completion 2017-05-15 3 sites Stand-alone
    Other conditions: Advanced Cancer, Metastatic Cancer, Colorectal Cancer, Non-small Cell Lung Cancer
    View official trial listing →
  • Completed NCT NCT02873975

    A Study of LY2606368 (Prexasertib) in Patients With Solid Tumors With Replicative Stress or Homologous Repair Deficiency

    Not yet reported Dana-Farber Cancer Institute 27 participants Est. completion 2021-07-01 1 site Stand-alone
    Other conditions: Advanced Cancers
    View official trial listing →
  • Completed NCT NCT03057145

    Combination Study of Prexasertib and Olaparib in Patients With Advanced Solid Tumors

    Not yet reported Geoffrey Shapiro, MD, PhD 29 participants Est. completion 2021-06-09 1 site Stand-alone
    Other conditions: Solid Tumor
    View official trial listing →
  • Completed NCT NCT03414047

    A Study of Prexasertib (LY2606368) in Platinum-Resistant or Refractory Recurrent Ovarian Cancer

    Not yet reported Eli Lilly and Company 172 participants Est. completion 2020-10-03 46 sites
    Other conditions: Ovarian Cancer
    View official trial listing →
  • Completed NCT NCT03495323

    A Study of Prexasertib (LY2606368), CHK1 Inhibitor, and LY3300054, PD-L1 Inhibitor, in Patients With Advanced Solid Tumors

    Not yet reported Dana-Farber Cancer Institute 17 participants Est. completion 2021-02-01 1 site
    Other conditions: Cancer
    View official trial listing →
  • Terminated NCT NCT03735446

    Prexasertib in Combination With MEC in Relapsed/Refractory AML and High Risk MDS - a Phase I Trial

    Not yet reported Dana-Farber Cancer Institute 2 participants Est. completion 2019-03-29 1 site
    Other conditions: Acute Myeloid Leukemia, Myelodysplastic Syndromes
    View official trial listing →
  • Completed NCT NCT04023669

    Evaluation of LY2606368 Therapy in Combination With Cyclophosphamide or Gemcitabine for Children and Adolescents With Refractory or Recurrent Group 3/Group 4 or SHH Medulloblastoma Brain Tumors

    Not yet reported St. Jude Children's Research Hospital 21 participants Est. completion 2025-01-13 1 site
    Other conditions: Brain Tumor, Brain Tumor, Recurrent, Brain Tumor, Refractory, Brain Tumor, Pediatric, Medulloblastoma, Medulloblastoma Recurrent, Medulloblastoma, Non-WNT/Non-SHH, Medulloblastoma, Non-WNT/Non-SHH, Group 3, Medulloblastoma, Non-WNT/Non-SHH, Group 4, Brain Cancer, CNS Cancer, CNS Tumor, CNS Neoplasm
    View official trial listing →
  • Completed NCT NCT04032080

    LY3023414 and Prexasertib in Metastatic Triple-negative Breast Cancer

    Not yet reported Baylor Research Institute 10 participants Est. completion 2022-11-26 1 site
    Other conditions: Triple Negative Breast Cancer
    View official trial listing →
  • Completed NCT NCT04095221

    A Study of the Drugs Prexasertib, Irinotecan, and Temozolomide in People With Desmoplastic Small Round Cell Tumor and Rhabdomyosarcoma

    Not yet reported, Not yet reported Memorial Sloan Kettering Cancer Center 21 participants Est. completion 2025-02-18 1 site
    Obstructive sleep apnea Other conditions: Desmoplastic Small Round Cell Tumor
    View official trial listing →
Efficacy history

Not yet reported.

Safety

Not yet reported.

Sources
Related On The Pen coverage

No related coverage yet.

This drug may be investigational and not yet approved for any use. Whether someone can join a clinical trial is determined only by that trial's own study team — On The Pen does not determine eligibility. Information here can change; always confirm current details on the official ClinicalTrials.gov listing or with the sponsor.